Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.49 |
| ▸ | PRCP | P42785 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437602 | 1.00 | ALDH1A1 (0.51) | ALDH1A1TSHREPHX2PRCPHSD17B10 | |
| SCHEMBL20748146 | 0.90 | PRCP (0.46) | ALDH1A1TSHREPHX2PRCPHSD17B10 | |
| SCHEMBL18761565 | 0.79 | PRCP (0.49) | PRCPHTR2CHTR2B | |
| SCHEMBL5160032 | 0.76 | EPHX1 (0.51) | TSHREPHX2PRCP | |
| SCHEMBL17437543 | 0.76 | EPHX1 (0.51) | TSHREPHX2PRCP | |
| SCHEMBL4827562 | 0.76 | EPHX1 (0.51) | TSHREPHX2PRCP | |
| SCHEMBL12529945 | 0.75 | PRCP (0.57) | PRCPHTR2CHTR2B | |
| SCHEMBL18591161 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHREPHX2HSD17B10L3MBTL1 | |
| SCHEMBL15329272 | 0.75 | PRCP (0.70) | PRCPHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL18555050 | 0.74 | ALDH1A1 (0.49) | ALDH1A1TSHREPHX2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | ALDH1A1 1695/4885TSHR 914/4885EPHX2 4652/4885 |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, TRPV1, SCN1A | ALDH1A1 1695/4885TSHR 914/4885EPHX2 4652/4885 |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | ALDH1A1 1872/4885TSHR 852/4885EPHX2 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.